Spero Therapeutics, Inc. Profile Avatar - Palmy Investing

Spero Therapeutics, Inc.

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product can…

Biotechnology
US, Cambridge [HQ]
Major Shareholders · Proxy Ben. Owners

Shareholders

Breakdown
Spero Therapeutics, Inc. can't present any analysts estimates at the moment detail analysis.
Intraday
Shares Outstanding
54,518,200
Volume
447,427
Volume on Avg.
289,968
Beneficial Owners Beta
SEC Source
Owner Shares Equivalence - $0.90 per share Last Form/Filing Last Transaction
10% Holder
- No data -
Officers/Directors Below 10%
- No data -
End of SPRO's Analysis
CIK: 1701108 CUSIP: 84833T103 ISIN: US84833T1034 LEI: - UEI: -
Secondary Listings
SPRO has no secondary listings inside our databases.